Physician profile
Levi Bachler
NPI 1134199227
$2,092.32
in general payments reported to CMS, 2019-2025
25 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $464 · 2023: $631 · 2024: $591 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $694.18 | 2022-2025 | |
| Lilly USA, LLC | $307.57 | 2022-2025 | Mounjaro, Trulicity |
| Corium, LLC | $144.79 | 2022-2024 | Azstarys |
| Novo Nordisk INC | $142.80 | 2022-2025 | Rybelsus, Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $119.75 | 2022 | |
| Pfizer INC. | $87.86 | 2023-2025 | |
| Tris Pharma INC | $54.76 | 2024-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $52.32 | 2023 | Quviviq |
| Cranial Technologies, INC | $51.32 | 2022-2024 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $42.63 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Boston Scientific Corporation | $40.98 | 2022-2023 | Wavewriter Alpha Prime 16 |
| Organon LLC | $40.25 | 2023-2024 | Nexplanon |
| Supernus Pharmaceuticals, INC. | $37.72 | 2024-2025 | Qelbree |
| Glaxosmithkline, LLC. | $34.92 | 2023-2024 | Arexvy, Shingrix |
| Vanda Pharmaceuticals INC. | $31.04 | 2024 | Fanapt |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.29 | 2022-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Axsome Therapeutics, INC. | $26.23 | 2024 | Auvelity |
| Novartis Pharmaceuticals Corporation | $23.80 | 2022 | |
| Ironshore Pharmaceuticals INC. | $23.71 | 2024 | |
| Abbott Laboratories | $22.57 | 2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $17.69 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.93 | 2025 | Caplyta |
| Ultragenyx Pharmaceutical INC. | $16.59 | 2022 | |
| Edwards Lifesciences Corporation | $16.58 | 2022 | |
| Exact Sciences Corporation | $15.04 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Levi Bachler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.